Related Experiment Video
Updated: Jan 12, 2026
Resting-State Connectivity and Neuroimaging of Prefrontal Cortex Activity During a Block-Design Yoga Asana Practice Using fNIRS
Published on: June 24, 2025
Meta-analysis of yoga-based mind-body interventions in the management of inflammatory bowel disease
Linjia Pan1, Xiaotong Chen2, Yiqi Wu2
1The Second Clinical College of Zhejiang Chinese Medical University, Hangzhou 310053 China.
Background:
Inflammatory bowel disease (IBD) affects millions worldwide and imposes both physical and psychological burdens. While current treatments have limitations, yoga-based mind-body interventions (YMBIs) show promise in improving symptoms and quality of life through physiological and stress-regulating pathways.
Objective:
This Meta-analysis seeks to comprehensively and objectively assess the efficacy of yoga-based mind-body interventions on psychological, physical, and inflammatory outcomes in patients with IBD.
Methods:
A comprehensive search was conducted in both international and Chinese databases including PubMed, EMBASE, Cochrane Library, Web of Science, Medline, China National Knowledge Infrastructure (CNKI), WanFang, and China Biomedical Literature Service System. Randomized controlled trials (RCTs) comparing YMBIs with standard care or placebo in IBD patients were pooled from inception to February 17, 2025. Data were analyzed using RevMan 5.4 and Stata 16.0, with standardized mean differences (SMDs) and 95 % confidence intervals (CIs) as effect measures.
Results:
Seven RCTs comprising 502 participants were included. The meta-analysis revealed that YMBIs significantly reduced anxiety (SMD = -0.56, 95 % CI [-0.77 to -0.36], P < 0.0001), depression (SMD = -3.45, 95 % CI [-5.52 to -1.37], P < 0.0001), and perceived stress (SMD = -0.70, 95 % CI [-1.00 to -0.39], P < 0.0001), while improving quality of life (SMD = 0.47, 95 % CI [0.17-0.77], P = 0.002). Effects on sleep quality (SMD = -1.98, 95 % CI [-3.98-0.02], P = 0.05) and disease activity (SMD = -0.26, 95 % CI [-0.52-0.01], P = 0.05) were modest, with borderline statistical significance.
Conclusion:
YMBIs alleviates psychological distress and enhance well-being in IBD patients, though their impact on disease progression remains uncertain. However, their effects on sleep quality and disease activity require further validation through high-quality clinical studies.
Systematic Review Registration:
https://www.crd.york.ac.uk/PROSPERO/view/CRD420250653339.
More Related Videos
12:22Mindfulness in Motion MIM: An Onsite Mindfulness Based Intervention MBI for Chronically High Stress Work Environments to Increase Resiliency and Work Engagement
Published on: July 1, 2015
05:06Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
Published on: July 14, 2023
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents